Financial Highlights for the Fiscal Year Ended March 31, 2025
Net sales increased by 2.2% year on year to 600,370 million yen. Operating profit was 5,706 million yen, up 2.7% year on year. Ordinary profit was 6,970 million yen, up 6.3% year on year. The interim net profit attributable to owners of parent was 7,308 million yen, up 25.1% year on year. ・In the core pharmaceutical wholesaling business, sales of products eligible for the price maintenance premium, original drug, vaccines, and test kits and treatments for influenza, increased. ・Operating income and ordinary income increased due to higher income in the pharmaceutical wholesaling business, improved profitability in other businesses, and foreign exchange gains on investment securities. ・In addition, net income increased significantly as a result of the sale of cross-shareholdings. ・ROE was 6.9%, the highest since FY2016